COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Eli Lilly And Co.
LY-CoV555, an antibody therapeutic for treatment and prevention of COVID-19
Phase I trial of LY-CoV555 in patients hospitalized with COVID-19
Phase I results expected by end of June 2020
Privately-held AbCellera Biologics Inc.
Moderna, Inc
mRNA-1273 Vaccine
Phase 2 study to begin in Q2, 2020
Phase 3 study to begin in July 2020
Kevzara (Repurposed drug)
Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
Regeneron Pharmaceuticals, Inc. (REGN)
InflaRx N.V.
IFX-1 for COVID-19 pneumonia
Phase 2 trial of IFX-1 in COVID-19 patients with severely progressed pneumonia in Netherlands
Beijing Defengrei Biotechnology Co. Ltd.
Amgen Inc.
Otezla (Repurposed drug)
Psoriasis drug Otezla to be tested as a potential treatment for COVID-19
Mesoblast Limited
Phase 2/3 trial of Remestemcel-L for COVID-19 acute respiratory distress syndrome
Mount Sinai Hospital in New York
AstraZeneca PLC
Farxiga (Repurposed drug)
Phase 3 trial of Farxiga as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure (DARE-19)
Saint Luke’s Mid America Heart Institute
Cyclacel Pharmaceuticals Inc.
Fadraciclib and Seliciclib
Clinical stage drug candidates Fadraciclib and Seliciclib to be tested as potential early treatments for inflammatory response observed in COVID-19 patients
University of Edinburgh

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products. Hundreds of Facebook employees staged a "virtual walkout" on Monday to protest the company's decision not to act on recent controversial posts by President Donald Trump on the social media platform. The employees criticized Facebook chief executive Mark Zuckerberg's decision to not moderate a post from Trump last Thursday.